Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

Isoform-Specific KRAS–Hexokinase 1 Interaction Affects Metabolism

DOI: 10.1158/2159-8290.CD-RW2019-189 Published February 2020
  • Article
  • Info & Metrics
Loading
  • Major Finding: KRAS4A, but not KRAS4B, directly interacts with hexokinase 1 (HK1) on outer mitochondrial membranes.

  • Concept: KRAS4A increases HK1 activity in vitro and enhances glycolytic flux in cancer cell lines.

  • Impact: This previously unidentified, isoform-specific KRAS function may be exploitable in cancer therapy.


Embedded Image

KRAS, the proto-oncogene most commonly mutated in cancer, encodes two splice variants: KRAS4A and KRAS4B. These variants are identical except for their fourth exons, which encode their C-terminal membrane-targeting domains. Activating mutations in the first or second exons give rise to oncogenic forms of both variants. Despite evolutionary conservation, no functional differences between the two isoforms have been conclusively identified. Amendola, Mahaffey, and colleagues found that KRAS4A interacted much more strongly with the ubiquitously expressed metabolic enzyme hexokinase 1 (HK1) than did KRAS4B. This interaction was dependent on prenylation of KRAS4A, which is required for membrane targeting. Additionally, palmitoylation—a modification that affects KRAS4A but not KRAS4B and allows for continuous cycling of RAS proteins from one membrane compartment to another—negatively regulated the interaction between HK1 and KRAS4A. Further supporting the interaction between KRAS4A and HK1, depalmitoylated KRAS4A and HK1 colocalized on the outer mitochondrial membrane (OMM), where HK1 normally resides. The association between KRAS4A and HK1 was dependent on GTP, implying an interaction between KRAS4A's G domain and HK1, and further experiments suggested that HK1 contains a functional RAS-binding domain. The observed colocalization of KRAS4A and HK1 on the OMM was shown to be required for their interaction, supporting the idea that the specificity of the isoform-specific interaction between HK1 and KRAS4A is due to the latter's membrane-targeting sequence. Functionally, biochemical experiments demonstrated a direct effect of KRAS4A on the allosteric feedback inhibition of HK1, which increased HK1 activity both in vitro and in human cancer cell lines, enhancing glycolytic flux. Together, these results indicate that HK1 is a KRAS effector specific to the 4A isoform and imply that KRAS4A-mediated HK1 regulation may contribute to the metabolic perturbations observed in KRAS-mutant tumor cells. Interestingly, HK1 inhibitors have been investigated as anticancer drugs, and these results suggest that it may be worthwhile to examine whether expression levels of the two KRAS isoforms affect tumors' susceptibility to these drugs.

Amendola CR, Mahaffey JP, Parker SJ, Ahearn IM, Chen WC, Zhou M, et al. KRAS4A directly regulates hexokinase 1. Nature 2019;576:482–6.

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.

  • ©2019 American Association for Cancer Research.
View Abstract
PreviousNext
Back to top
Cancer Discovery: 10 (2)
February 2020
Volume 10, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Isoform-Specific KRAS–Hexokinase 1 Interaction Affects Metabolism
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Isoform-Specific KRAS–Hexokinase 1 Interaction Affects Metabolism
Cancer Discov February 1 2020 (10) (2) OF10; DOI: 10.1158/2159-8290.CD-RW2019-189

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Isoform-Specific KRAS–Hexokinase 1 Interaction Affects Metabolism
Cancer Discov February 1 2020 (10) (2) OF10; DOI: 10.1158/2159-8290.CD-RW2019-189
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Structures Identify Selpercatinib and Pralsetinib Resistance Mechanisms
  • Computational Tool Characterizes Previously Unidentified Tumor Subtypes
  • Deep Learning Algorithm Aids Breast Cancer Detection by Mammography
Show more Research Watch

Metabolism

  • Recruited Nerves Supply Serine to Support Pancreatic Cancer Growth
  • Relapse-Driving AML Cells Exhibit Pyrimidine-Synthesis Dependency
  • Serine Restriction Alters Sphingolipid Synthesis to Lower Tumor Growth
Show more Metabolism
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement